STOCK TITAN
  1. Home
  2. News
  3. PFE

Pfizer Inc. - PFE STOCK NEWS

Welcome to our dedicated news page for Pfizer (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pfizer's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pfizer's position in the market.

News
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Rhea-AI Summary
Pfizer Inc. (PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 10:50 a.m. EST. The webcast can be accessed on Pfizer's investor website, with the transcript and webcast replay available within 24 hours after the live discussion and accessible for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
conferences
-
News
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Rhea-AI Summary
PFE and Astellas Pharma Inc. (4503) announced that the FDA approved a supplemental New Drug Application for XTANDI, making it the first and only androgen receptor signaling inhibitor approved for nonmetastatic castration-sensitive prostate cancer treatment with or without a GnRH analog therapy. This approval follows expedited development and review programs based on results from the Phase 3 EMBARK trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
none
-
News
Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting
Rhea-AI Summary
Pfizer Inc. will present data on advancements in the treatment of hemophilia, sickle cell disease, and blood cancers at the ASH Annual Meeting. Key presentations include results from the Phase 3 BASIS trial of marstacimab in hemophilia, Phase 2/3 results from the GBT601 study in sickle cell disease, and data on ELREXFIO for multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none
News
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Rhea-AI Summary
Pfizer Inc. invites investors and the general public to view a webcast of a discussion with Aamir Malik, Chief Business Innovation Officer, Executive Vice President, at the Truist Securities BioPharma Symposium on November 9, 2023. The webcast will be available on Pfizer's website and the transcript and replay will be accessible for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
conferences
-
News
Pfizer Reports Third-Quarter 2023 Results
Rhea-AI Summary
Pfizer Inc. reports Q3 2023 revenues of $13.2 billion, driven by growth in non-COVID products. Diluted loss per share of $(0.42) and adjusted diluted loss per share of $(0.17) due to non-cash inventory write-offs. Reaffirms full-year 2023 revenue guidance of $58.0 to $61.0 billion and adjusted diluted EPS of $1.45 to $1.65.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
earnings
-
News
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
Rhea-AI Summary
Pfizer receives FDA approval for PENBRAYA, a pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
fda approval
News
ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023
Rhea-AI Summary
ViiV Healthcare to present key data at the 19th Annual European AIDS Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.09%
Tags
conferences
-
News
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
Rhea-AI Summary
Everest Medicines announces FDA approval for VELSIPITY™ (etrasimod) for ulcerative colitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
fda approval
-
News
Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023
Rhea-AI Summary
Astellas Pharma to present new research results at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
none
News
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance
Rhea-AI Summary
Pfizer amends supply agreement with US government for Paxlovid and updates Full-Year 2023 Guidance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock PFE logo
Pfizer Inc.

NYSE:PFE

PFE Rankings

#67 Ranked by Market Cap
#4118 Ranked by Stock Gains
#450 Ranked by Dividends

PFE Stock Data

146.43B
5.64B
0.05%
69.93%
1.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Palo Alto

About PFE

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.